Video

What to Expect When Going on a PARP Inhibitor for Ovarian Cancer

Chemotherapy and PARP inhibitors may share some side effects, but there are some major differences between the two when it comes to treating ovarian cancer.

PARP inhibitors are different than most other ovarian cancer treatments because they are oral agents administered daily.

However, according to Ursula A. Matulonis, M.D., chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute, there are some unifying side effects between PARP inhibitors and traditional ovarian cancer treatments, such as chemotherapy. These include fatigue and gastrointestinal issues.

While, chemotherapy-induced side effects can be long-lasting, most associated with PARP inhibitors stop after about four to six weeks of treatment, she added.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.
Related Content